Warning: fopen(/home/virtual/enm-kes/journal/upload/ip_log/ip_log_2025-06.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 100 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 101
Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Copyright © 2017 Korean Endocrine Society
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.
Age, yr | Prevalence of hypercholesterolemia, %a | ||
---|---|---|---|
Total | Male | Female | |
≥30b | 19.5 | 16.9 | 22.1 |
30–49 | 12.1 | 14.7 | 9.4 |
50–64 | 24.5 | 18.1 | 30.9 |
≥65 | 30.3 | 20.8 | 37.6 |
Age, yr | Prevalence of hypertriglyceridemia, %a | ||
---|---|---|---|
Total | Male | Female | |
≥30b | 16.8 | 23.9 | 10.4 |
30–49 | 17.3 | 27.5 | 7.9 |
50–64 | 17.9 | 24.1 | 12.2 |
≥65 | 13.9 | 14.9 | 13.0 |
Values are expressed as percentage.
aAwareness: proportion of the population diagnosed by a doctor; bAll over 30 years old; cTreatment: proportion of the population taking a lipid-lowering medication ≥20 days a month; dRate of control (in those with hypercholesterolemia): proportion of the population with hypercholesterolemia with a serum total cholesterol level <200 mg/dL; eRate of control (in the treated): proportion of the population with a serum total cholesterol level <200 mg/dL among those treated with lipid-lowering medications.
Values are expressed as mean±standard error.
KNHANES, Korean National Health and Nutrition Examination Survey.
aAwareness: proportion of the population diagnosed by a doctor; bTreatment: proportion of the population taking a lipid-lowering medication ≥20 days a month; cRate of control (in those with hypercholesterolemia): proportion of the population with hypercholesterolemia with a serum total cholesterol level <200 mg/dL; dRate of control (in the treated): proportion of the population with a serum total cholesterol level <200 mg/dL among those treated with lipid-lowering medications.
Age, yr | Prevalence of hypercholesterolemia, %a | ||
---|---|---|---|
Total | Male | Female | |
≥30b | 19.5 | 16.9 | 22.1 |
30–49 | 12.1 | 14.7 | 9.4 |
50–64 | 24.5 | 18.1 | 30.9 |
≥65 | 30.3 | 20.8 | 37.6 |
Variable | Hypertriglyceridemia, %a | |||||
---|---|---|---|---|---|---|
2010 | 2011 | 2012 | 2013 | 2014 | 2015 | |
Total | 13.5±0.6 | 13.8±0.5 | 14.5±0.6 | 14.9±0.6 | 14.6±0.7 | 17.9±0.7 |
Male | 13.0±0.9 | 12.6±0.9 | 12.2±0.8 | 13.6±0.8 | 13.9±1.0 | 16.5±1.0 |
Female | 13.4±0.7 | 14.9±0.7 | 16.4±0.9 | 15.9±0.8 | 15.0±0.8 | 19.1±0.8 |
20 Years and over, age-adjusted | 1988–1994 | 1999–2002 | 2003–2006 | 2007–2010 | 2011–2014 |
---|---|---|---|---|---|
Population with hypercholesterolemia, %a | |||||
Both sexes | 22.8 | 25.0 | 27.7 | 27.4 | 27.8 |
Male | 21.1 | 25.3 | 27.7 | 28.0 | 28.4 |
Female | 24.0 | 24.3 | 27.4 | 26.7 | 27.3 |
Population with high cholesterol, %b | |||||
Both sexes | 20.8 | 17.3 | 16.3 | 13.7 | 11.9 |
Male | 19.0 | 16.4 | 15.1 | 12.6 | 10.8 |
Female | 22.0 | 17.8 | 17.1 | 14.4 | 12.7 |
Mean serum total cholesterol level, mg/dL | |||||
Both sexes | 206 | 203 | 200 | 196 | 192 |
Male | 204 | 202 | 198 | 194 | 189 |
Female | 207 | 204 | 202 | 198 | 195 |
Age, yr | Prevalence of hypertriglyceridemia, %a | ||
---|---|---|---|
Total | Male | Female | |
≥30b | 16.8 | 23.9 | 10.4 |
30–49 | 17.3 | 27.5 | 7.9 |
50–64 | 17.9 | 24.1 | 12.2 |
≥65 | 13.9 | 14.9 | 13.0 |
Variable | Hypertriglyceridemia, %a | |||||
---|---|---|---|---|---|---|
2010 | 2011 | 2012 | 2013 | 2014 | 2015 | |
Total | 16.6±0.7 | 16.2±0.7 | 16.8±0.8 | 17.1±0.7 | 17.9±0.8 | 16.8±0.8 |
Male | 23.9±1.3 | 23.9±1.2 | 21.1±1.3 | 23.8±1.3 | 26.8±1.3 | 24.6±1.5 |
Female | 9.7±0.7 | 8.9±0.7 | 12.5±0.9 | 10.9±0.7 | 9.8±0.8 | 9.7±0.8 |
Age, yr | Total | Male | Female |
---|---|---|---|
Awarenessa | |||
≥30b | 57.7 | 51.4 | 62.4 |
30–49 | 32.3 | 32.1 | 32.6 |
50–64 | 62.9 | 61.7 | 63.6 |
≥65 | 77.9 | 77.5 | 78.0 |
Treatmentc | |||
≥30b | 45.5 | 39.8 | 49.9 |
30–49 | 19.3 | 18.6 | 20.5 |
50–64 | 48.7 | 50.4 | 47.7 |
≥65 | 69.9 | 69.9 | 69.9 |
Rate of control (in those with hypercholesterolemia)d | |||
≥30b | 39.7 | 37.1 | 41.7 |
30–49 | 15.8 | 15.8 | 15.8 |
50–64 | 42.8 | 47.4 | 40.0 |
≥65 | 61.6 | 68.4 | 59.0 |
Rate of control (in the treated)e | |||
≥30b | 84.3 | 88.4 | 81.8 |
30–49 | 76.5 | 76.3 | 77.0 |
50–64 | 84.9 | 90.2 | 81.5 |
≥65 | 85.9 | 93.6 | 82.9 |
Variable | 2005 (third KNHANES) | 2007–2009 (fourth KNHANES) | 2010–2012 (fifth KNHANES) | 2013–2015 (sixth KNHANES) |
---|---|---|---|---|
Awarenessa | ||||
Total | 24.0±2.4 | 38.8±1.5 | 47.4±1.4 | 57.7±1.3 |
Male | 24.4±4.2 | 37.0±2.2 | 45.2±2.3 | 51.4±2.0 |
Female | 23.8±3.0 | 40.3±1.8 | 49.1±1.7 | 62.4±1.6 |
Treatmentb | ||||
Total | 17.3±2.1 | 26.9±1.3 | 37.3±1.4 | 45.5±1.3 |
Male | 17.5±3.6 | 24.6±1.9 | 35.8±2.0 | 39.8±2.0 |
Female | 17.1±2.6 | 28.6±1.6 | 38.4±1.8 | 49.9±1.6 |
Rate of control (in those with hypercholesterolemia)c | ||||
Total | 10.8±1.7 | 20.3±1.1 | 29.9±1.2 | 39.7±1.2 |
Male | 11.0±2.5 | 20.2±1.7 | 28.7±1.8 | 37.1±1.9 |
Female | 10.6±2.2 | 20.3±1.4 | 30.9±1.6 | 41.7±1.5 |
Rate of control (in the treated)d | ||||
Total | 62.3±6.6 | 73.5±2.2 | 78.8±1.6 | 84.3±1.2 |
Male | 63.1±11.0 | 80.6±3.3 | 79.3±2.8 | 88.4±1.8 |
Female | 61.8±7.9 | 68.8±2.9 | 78.5±1.9 | 81.8±1.6 |
aSerum total cholesterol ≥240 mg/dL or taking lipid-lowering medications; bAll over 30 years old.
Values are expressed as mean±standard error. aSerum total cholesterol ≥240 mg/dL or taking lipid-lowering medications.
aSerum total cholesterol ≥240 mg/dL or taking cholesterol-lowering medications; bSerum total cholesterol ≥240 mg/dL.
aSerum triglyceride level ≥200 mg/dL; bAll over 30 years old.
Values are expressed as mean±standard error. aSerum triglyceride level ≥200 mg/dL.
Values are expressed as percentage. aAwareness: proportion of the population diagnosed by a doctor; bAll over 30 years old; cTreatment: proportion of the population taking a lipid-lowering medication ≥20 days a month; dRate of control (in those with hypercholesterolemia): proportion of the population with hypercholesterolemia with a serum total cholesterol level <200 mg/dL; eRate of control (in the treated): proportion of the population with a serum total cholesterol level <200 mg/dL among those treated with lipid-lowering medications.
Values are expressed as mean±standard error. KNHANES, Korean National Health and Nutrition Examination Survey. aAwareness: proportion of the population diagnosed by a doctor; bTreatment: proportion of the population taking a lipid-lowering medication ≥20 days a month; cRate of control (in those with hypercholesterolemia): proportion of the population with hypercholesterolemia with a serum total cholesterol level <200 mg/dL; dRate of control (in the treated): proportion of the population with a serum total cholesterol level <200 mg/dL among those treated with lipid-lowering medications.